A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia

Part of paid clinical trials in New York, New York.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT07313852
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • B-ALL
  • B-Cell Acute Lymphoblastic Leukemia, Adult
  • B-cell Acute Lymphoblastic Leukemia

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Not accepted

Interventions

  • Blinatumomab Injection — DRUG
    Blinatumomab given via subcutaneous injection

Study Details

The purpose of this study is to find out whether combining inotuzumab and blinatumomab is a safe and effective treatment for participants with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL).

Key Dates

Start date
Jun 30, 2026
Status verified
Apr 2026
Primary completion
Jan 31, 2029
Completion
Jan 31, 2029

Study Design

Enrollment
26 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Phase I: Participants With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
    Participants will be newly diagnosed with CD19+ and CD22+ B-cell Acute Lymphoblastic Leukemia
  • Experimental: Phase II: Participants With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
    Participants who receive at least one dose of the Inotuzumab will be evaluable for the primary endpoint

Primary Outcome Measure

Phase I: Maximum Tolerated Dose/MTD [ Time Frame: up to 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Memorial Sloan Kettering Cancer Center (All Protocol Activities)New YorkNew York10065
Jae Park, MD
646-608-3743

Find similar trials in New York, NY

By research site
Memorial Sloan Kettering Cancer Center (All Protocol Activities)· New York, NY

Related Studies